Today: 8 November 2025
Subscribe
Browse Category

Pharmaceutical Industry News 18 October 2025 - 5 November 2025

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Stock Price & Recent Performance 📈 Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings report stockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32 investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now
5 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week range ($20.92 – $28.00) marketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s (a ~10% jump) following its government pricing deal announcement marketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However,
4 November 2025
 ·  ·  ·  ·  ·  · 
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Company Overview & History Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” (knowledge) and “vue” (view), reflecting a vision of insight-driven care en.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter (OTC) medicines to skincare and baby care. Today its portfolio spans three segments investing.com: Formally incorporated in 2022, Kenvue began trading on the NYSE (ticker KVUE) in May 2023 after a highly anticipated IPO en.wikipedia.org. The IPO raised $3.8 billion – the largest U.S. listing in nearly two years – and
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Company Overview & 2025 Developments Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals (pets) and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50% proclinical.com proclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock. Recent 2025 highlights: The first half of 2025 saw Zoetis deliver solid growth. In
4 November 2025
 ·  ·  ·  ·  · 
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

High-Flying Share Price and Recent Performance 🚀 As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89 the day prior stockinvest.us. That single-day gain of +30.8% crowned CURR (now AVRW) as one of the market’s top percentage gainers. In fact, the stock has rallied five days in a row, more than doubling (+104% in two weeks) amid surging volume stockinvest.us. This momentum continued into Nov 3, with an opening trade around $3.52 and only a modest pullback
3 November 2025
 ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech stockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21 stockanalysis.com, versus
31 October 2025
 ·  ·  ·  ·  · 
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

BMY Stock Bounces After Earnings – Recent Performance Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 (closing at $42.99) marketbeat.com. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector (which was roughly flat to slightly up over the same period) nasdaq.com. By comparison, an index of large pharmaceutical stocks was
30 October 2025
 ·  ·  ·  · 
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

CI Stock Price and Recent Trend Cigna’s stock has pulled back modestly in late October after a strong run earlier in the year. According to market data, CI closed at $299.12 on Oct 29, 2025, down about 3% from the previous close stockanalysis.com. The dip followed weakness in broader managed-care stocks amid concerns about healthcare costs and policy. In pre-market trading Oct 30, CI rebounded to about $303 (up ~1.3%) reuters.com. Over the past year, CI shares have traded between roughly $257 and $350 stockanalysis.com, reflecting volatility in the insurance sector. Despite the pullback, Cigna’s valuation metrics remain attractive: at
30 October 2025
 ·  ·  ·  · 
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran (NTLA-2001) due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy (ATTR-CM) – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety
27 October 2025
 ·  ·  ·  · 
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst
27 October 2025
 ·  ·  ·  ·  ·  · 
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating is “Buy” (with average target ~$125) based on Gilead’s diversified portfolio and innovation investing.com ts2.tech. As management shifts into high gear on oncology and global health programs (e.g. a PEPFAR-backed plan to deliver Yeztugo overseas), the long-term outlook is that Gilead’s multiple drivers will more than offset sector risks. Sources: Recent financial filings and earnings commentary gilead.com stockanalysis.com; industry news
18 October 2025
 ·  ·  ·  · 
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Key Facts – October 18, 2025 RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and a significant financing boost. In pre-market trading, RANI shares jumped over +150%, and the rally continued after the opening bell ts2.tech ts2.tech. The stock — which had closed at just $0.47 the day before — briefly hit about $1.37 intraday (nearly a 3× gain) on extremely heavy volume ts2.tech ts2.tech. By midday, RANI was still trading around $1.30, up ~180% on the day, marking a stunning one-day surge
18 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop